These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 2498095)

  • 41. [Postantibiotic effects and postantibiotic effects of subinhibitory levels of quinolines on Pseudomonas aeruginosa].
    Hostacká A
    Epidemiol Mikrobiol Imunol; 1996 May; 45(2):56-8. PubMed ID: 8756401
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Aminoglycoside Concentrations Required for Synergy with Carbapenems against Pseudomonas aeruginosa Determined via Mechanistic Studies and Modeling.
    Yadav R; Bulitta JB; Schneider EK; Shin BS; Velkov T; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28893782
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Comparative bactericidal activity of imipenem and other antibiotics against Pseudomonas aeruginosa].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1988 May; 36(5):472-6. PubMed ID: 3136428
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Antimicrobial susceptibility of imipenem-resistant Pseudomonas aeruginosa.
    Higgins PG; Fluit AC; Milatovic D; Verhoef J; Schmitz FJ
    J Antimicrob Chemother; 2002 Aug; 50(2):299-301. PubMed ID: 12161417
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparative In Vitro Efficacy of Doripenem and Imipenem Against Multi-Drug Resistant Pseudomonas aeruginosa.
    Wali N; Mirza IA
    J Coll Physicians Surg Pak; 2016 Apr; 26(4):297-301. PubMed ID: 27097701
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of inhibitory and bactericidal activity of antipseudomonal antibiotics against Pseudomonas aeruginosa isolates from cystic fibrosis patients.
    Ansorg R; Müller KD; Wiora J
    Chemotherapy; 1990; 36(3):222-9. PubMed ID: 2110878
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance to imipenem and zinc in clinical isolates of Pseudomonas aeruginosa.
    Velasco C; Rodríguez JM; Conejo MC; Pascual A
    Int J Antimicrob Agents; 2006 Oct; 28(4):377-8. PubMed ID: 16965905
    [No Abstract]   [Full Text] [Related]  

  • 48. In vitro effect of imipenem on Acinetobacter baumannii.
    Hostacká A
    Pharmazie; 1999 Jan; 54(1):70-2. PubMed ID: 9987801
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bactericidal activity of two different dosage regimens of imipenem in an in-vitro dynamic model.
    Maggiolo F; Taras A; Frontespezi S; Bottari F; Legnani MC; Suter F
    J Antimicrob Chemother; 1993 Aug; 32(2):295-300. PubMed ID: 8226431
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program.
    Ellis JM; Kuti JL; Nicolau DP
    Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ultrastructural modifications induced by imipenem and their implications in the pathogenicity of Pseudomonas aeruginosa.
    Carlone N; Ferrero M; Cuffini A; Cavallo G
    Chemioterapia; 1987 Jun; 6(2 Suppl):73-4. PubMed ID: 3151357
    [No Abstract]   [Full Text] [Related]  

  • 52. [Bactericidal activity of biapenem against various efflux system mutants of Pseudomonas aeruginosa].
    Hiraishi T; Miyata A; Takata T; Araake M; Ogawa H; Gotoh N; Nishino T
    Jpn J Antibiot; 2002 Feb; 55(1):67-76. PubMed ID: 11977922
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In vitro antimicrobial activity of imipenem plus amikacin or polymyxin B against carbapenem-resistant Pseudomonas aeruginosa isolates.
    Wilhelm CM; Nunes LS; Martins AF; Barth AL
    Diagn Microbiol Infect Dis; 2018 Oct; 92(2):152-154. PubMed ID: 29891185
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals.
    Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP
    Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pharmacodynamic effects of amikacin, ciprofloxacin and imipenem on growing and non-growing Escherichia coli and Pseudomonas aeruginosa.
    Svensson E; Hanberger H; Nilsson M; Nilsson LE
    Clin Microbiol Infect; 1999 Mar; 5(3):140-148. PubMed ID: 11856238
    [TBL] [Abstract][Full Text] [Related]  

  • 56. ISPa46, a novel insertion sequence in the oprD porin gene of an imipenem-resistant Pseudomonas aeruginosa isolate from a cystic fibrosis patient in Marseille, France.
    Diene SM; L'homme T; Bellulo S; Stremler N; Dubus JC; Mely L; Leroy S; Degand N; Rolain JM
    Int J Antimicrob Agents; 2013 Sep; 42(3):268-71. PubMed ID: 23880169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. In-vitro activity of meropenem imipenem, the penem HRE 664 and ceftazidine against clinical isolates from West Germany.
    Bauernfeind A; Jungwirth R; Schweighart S
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():73-84. PubMed ID: 2509418
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Once versus thrice daily tobramycin alone and in combination with ceftazidime, ciprofloxacin and imipenem in an in vitro pharmacodynamic model.
    Zelenitsky SA; Karlowsky JA; Hoban DJ; Kabani A; Zhanel GG
    Chemotherapy; 1998; 44(1):1-6. PubMed ID: 9444401
    [TBL] [Abstract][Full Text] [Related]  

  • 59. In vitro antibacterial activity of rifampicin in combination with imipenem, meropenem and doripenem against multidrug-resistant clinical isolates of Pseudomonas aeruginosa.
    Hu YF; Liu CP; Wang NY; Shih SC
    BMC Infect Dis; 2016 Aug; 16(1):444. PubMed ID: 27553962
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Protection of Enterococcus faecalis in mixed cultures with carbapenemase-producing Escherichia coli and Bacteroide fragilis: effect of the bacterial load.
    Sevillano D; Aguilar L; Alou L; Giménez MJ; Cafini F; González N; Prieto J
    Rev Esp Quimioter; 2013 Sep; 26(3):220-5. PubMed ID: 24080888
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.